Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 - Test2 - elhamkhani - TriplyDB

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q24534620

about

HIV-1 entry inhibitors: an overview Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent HIV entry inhibitors: mechanisms of action and resistance pathways V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections.Closing the door to human immunodeficiency virus.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism.Drug interactions with new and investigational antiretrovirals.Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.HIV entry inhibitors and their potential in HIV therapy Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.A small set of succinct signature patterns distinguishes Chinese and non-Chinese HIV-1 genomes.Response normalized liquid chromatography nanospray ionization mass spectrometry.Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV A diagnostic HIV-1 tropism system based on sequence relatedness.CCR5 conformations are dynamic and modulated by localization, trafficking and G protein association Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug Oral CCR5 inhibitors: will they make it through?Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.CCR5 is a receptor for Staphylococcus aureus leukotoxin ED.Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.Recent advances in delivery systems for anti-HIV1 therapy.New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists

P2860

Q24645525-F411A4DA-BC24-42F7-8A67-0D3BE53B6A7B Q24656023-AA27AC07-5205-4808-AA0F-6A589B71CACF Q28296162-F44043A6-6F3B-441A-AA4D-0C7DB23B7FE4 Q28469283-725D26E4-0564-45A2-B57A-34DF9FE7A3A0 Q28477257-9DA00A10-D4E4-4E65-A17B-3C0C608F65EC Q28478341-43617330-38EE-44D3-AD57-3A30E6CCFA66 Q28481687-706D06F9-1C02-4009-B86C-9A60CD008EEF Q30359545-D4EF3B16-0F64-4EEC-B678-59F7E0212A5E Q30428089-57EBF884-A39B-4CA8-AEC8-49B2F6F2E681 Q30486707-44089785-9B5A-4186-BB45-A7766D584390 Q33455862-DCB4AB8E-F8A3-46CC-BB09-FC2D9160EFD2 Q33759112-C891057A-7A97-4C72-9B32-7021D9B050E1 Q33801821-6109B9DC-0271-4344-A342-504DC72EEC0E Q33822912-024032F1-C461-46DD-9D92-D3909CF0ED2A Q33951977-B7CA495D-13F2-4622-8F43-626028D01339 Q33961704-D4671FB5-104E-4FEA-A74E-3A9D201EAF61 Q34038718-281529ED-8B04-4A62-ADE4-C97A25F7BBAC Q34216388-FD34A456-92C5-4047-B681-67D303FB7746 Q34568280-DDF0B130-6DA6-4BB3-86D6-84DB3F8B3772 Q34571010-59C31AA4-62BC-4D72-B5F4-839C7E3021DB Q34595921-E6F0B7D9-1CF4-43E7-95AB-24164ABF3F0B Q34597465-86CE37C9-EDE2-4D40-9DEC-55F2C88EFA0D Q34634310-90FC1789-DE8B-4545-AD32-D4822A94C585 Q34674281-BCBEE83D-23CE-4A54-A61C-E9E179695F1D Q34682512-5516FA5A-F9EC-410A-B253-D8748347A1A3 Q34757951-8ED038B1-05DF-4A08-A606-039F5ACA0E89 Q34939533-F54D84EA-A140-451B-9BE4-F71F9BED2C73 Q34983107-31A618A3-D0E6-488E-8418-984E96EC1EFC Q35106596-E4222876-3266-4D27-9609-C7613E1A7BFC Q35400327-4A2306F2-C028-42E9-B732-2C7780C97E02 Q35557216-E05EB280-D205-412A-86BE-D120017CC7F8 Q35635933-A5CFD10F-BE00-465C-A5D5-133BADE2E1EA Q35665842-33D34B4F-24FD-4702-8FB2-E6186EA82E48 Q36458354-6AFA1FBD-571E-4070-9383-8604BB77A532 Q36459685-F85B5DFB-ACC9-461F-BF69-5F7BC440E0DD Q36508062-A1E3897F-EC27-4E5D-9F5F-E824E3671000 Q36541747-F253E1AC-1322-4C9A-9B67-08F99E89BE4F Q36607127-AE0480E5-C881-49E1-ACA9-400854EE168C Q36761854-5A9C8B12-1AAB-48CD-912B-21436CA5FA8D Q36823525-73951179-3746-4806-97E4-547291054209

P2860

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q24534620

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Discovery and characterization ...... immunodeficiency virus type 1

@ast

Discovery and characterization ...... immunodeficiency virus type 1

@en

Discovery and characterization ...... immunodeficiency virus type 1

@en-gb

Discovery and characterization ...... immunodeficiency virus type 1

@nl

type

label

Discovery and characterization ...... immunodeficiency virus type 1

@ast

Discovery and characterization ...... immunodeficiency virus type 1

@en

Discovery and characterization ...... immunodeficiency virus type 1

@en-gb

Discovery and characterization ...... immunodeficiency virus type 1

@nl

prefLabel

Discovery and characterization ...... immunodeficiency virus type 1

@ast

Discovery and characterization ...... immunodeficiency virus type 1

@en

Discovery and characterization ...... immunodeficiency virus type 1

@en-gb

Discovery and characterization ...... immunodeficiency virus type 1

@nl

P1433

Q24534620-8A166C69-D8CF-4FDF-9ADB-FAEF7DFBF0CA

P1476

Q24534620-B1F80875-A8F6-429D-B559-3BC9D63178B6

P2093

Q24534620-02837070-D350-467A-ABB7-1F017F9ACAF8

Q24534620-040FBAB4-4A74-492E-AA58-7C354C85738D

Q24534620-2012FC22-9B5D-4814-9E79-D7BEE4E68028

Q24534620-228C5356-512A-41A7-A3D7-9239DDFF5B36

Q24534620-2A3BECE9-4AEC-42E2-BF15-15CCFDEA7E01

Q24534620-2CAA96D0-7283-43EE-AE74-A9C3D9EF7319

Q24534620-361E66BB-D6A6-4949-8515-66B34163DCCE

Q24534620-4036FDED-3052-499E-AF8C-6219DB945181

Q24534620-4B4D067F-BD9B-45D3-8455-9A03A1EA04E5

Q24534620-5D630BC5-7170-4920-BBE1-C3E46EB6CCE0

P2860

Q24534620-0FA80775-D942-4A45-9A41-482C972D067F

Q24534620-217B7582-33A7-43FF-B3C2-39745F5E0DAE

Q24534620-326EFD95-AE0C-4A3C-84AE-DAEE59F0BCA4

Q24534620-39EDC410-D649-4186-9162-2F06EA67BE83

Q24534620-4297B8B2-BD50-4E08-B8DB-4A5DABF63795

Q24534620-56E935A9-12BB-4C35-8A6D-DCF6D7EC9422

Q24534620-58C6FB15-769D-4834-BD8F-FE8FEA8B8699

Q24534620-5DE7300C-B112-446F-9045-79468BA934A5

Q24534620-630B074C-6D26-4D59-A8EE-01D88450DE31

Q24534620-66F458F5-580C-4EC8-8F9C-9C8127CFBCEE

P304

Q24534620-0A8C9DE9-BC49-473A-BA4B-26DA754F6CBC

P31

Q24534620-97CE6197-8C80-4D07-80F1-BD130010E169

P356

Q24534620-943742E7-FB1F-401F-824D-71D3CE7BB6BB

P407

Q24534620-8F747EA8-E028-4DCB-B2B2-B4DF1B55A7E8

P433

Q24534620-0F4B1507-A65B-449C-BCFD-77CB3548B38F

P478

Q24534620-6645E39A-2AB8-4F38-8F6F-52414A9536A6

P577

Q24534620-5DB37DBC-C8C5-476A-A23A-52046E9E2983

P5875

Q24534620-123337B2-6669-4D1E-A8A0-FF72478780D8

P698

Q24534620-C96F6A23-02B4-40B5-AB2A-9B71E131A299

P921

Q24534620-AB8B74BE-83B5-42FA-B43E-2EDA013925CF

P932

Q24534620-BED1DB50-1149-408B-B1AC-429B289C501F

P356

AAC.49.12.4911-4919.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Discovery and characterization ...... immunodeficiency virus type 1

@en

P2093

Bahige M Baroudy

http://www.w3.org/2001/XMLSchema#string

Catherine Pugliese-Sivo

http://www.w3.org/2001/XMLSchema#string

Cecile Tremblay

http://www.w3.org/2001/XMLSchema#string

Chuan-Chu Chou

http://www.w3.org/2001/XMLSchema#string

Gregory R Reyes

http://www.w3.org/2001/XMLSchema#string

Jayaram R Tagat

http://www.w3.org/2001/XMLSchema#string

Julie M Strizki

http://www.w3.org/2001/XMLSchema#string

Kathleen Cox

http://www.w3.org/2001/XMLSchema#string

Lisa Wojcik

http://www.w3.org/2001/XMLSchema#string

Martin Hirsch

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Virus entry as a target for anti-HIV intervention

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highl

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Protein design of an HIV-1 entry inhibitor.

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

P304

4911-4919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.12.4911-4919.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7464951

http://www.w3.org/2001/XMLSchema#string

P698

16304152

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

1315929

http://www.w3.org/2001/XMLSchema#string